NASDAQ:ZNTL

Zentalis Pharmaceuticals Competitors

$50.68

+0.40 (+0.80 %)

(As of 04/16/2021 04:00 PM ET)

Add

Compare

Today's Range

$48.01

Now: $50.68▼

$52.50

50-Day Range

$37.41

MA: $43.03▼

$50.85

52-Week Range

$23.50

Now: $50.68▼

$61.29

Volume331,133 shs

Average Volume290,969 shs

Market Capitalization$2.08 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Vs. BBIO, MRTX, RARE, ARWR, GWPH, and ASND

Should you be buying ZNTL stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Zentalis Pharmaceuticals, including BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals (GWPH), and Ascendis Pharma A/S (ASND).

Zentalis Pharmaceuticals vs. BridgeBio Pharma Stock

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Valuation and Earnings

This table compares Zentalis Pharmaceuticals and BridgeBio Pharma's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BridgeBio Pharma	$40.56 million	201.80	$-260,590,000.00	($2.48)	-22.16

Zentalis Pharmaceuticals has higher earnings, but lower revenue than BridgeBio Pharma.

Profitability

This table compares Zentalis Pharmaceuticals and BridgeBio Pharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	N/A	N/A
BridgeBio Pharma	N/A	-109.88%	-48.54%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Zentalis Pharmaceuticals and BridgeBio Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	0	0	7	0	3.00
BridgeBio Pharma	0	1	9	0	2.90

Zentalis Pharmaceuticals currently has a consensus target price of $56.4286, indicating a potential upside of 14.93%. BridgeBio Pharma has a consensus target price of $72.8889, indicating a potential upside of 32.65%. Given BridgeBio Pharma's higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Zentalis Pharmaceuticals.

Institutional & Insider Ownership

67.1% of Zentalis Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.5% of BridgeBio Pharma shares are owned by institutional investors. 40.3% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

BridgeBio Pharma beats Zentalis Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Zentalis Pharmaceuticals vs. Mirati Therapeutics Stock

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Mirati Therapeutics (NASDAQ:MRTX) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Valuation and Earnings

This table compares Zentalis Pharmaceuticals and Mirati Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Mirati Therapeutics	$3.34 million	2,398.14	$-213,260,000.00	($5.69)	-27.80

Zentalis Pharmaceuticals has higher earnings, but lower revenue than Mirati Therapeutics.

Profitability

This table compares Zentalis Pharmaceuticals and Mirati Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	N/A	N/A
Mirati Therapeutics	N/A	-60.01%	-54.21%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Zentalis Pharmaceuticals and Mirati Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	0	0	7	0	3.00
Mirati Therapeutics	1	5	10	0	2.56

Zentalis Pharmaceuticals currently has a consensus target price of $56.4286, indicating a potential upside of 14.93%. Mirati Therapeutics has a consensus target price of $218.5714, indicating a potential upside of 37.21%. Given Mirati Therapeutics' higher possible upside, analysts plainly believe Mirati Therapeutics is more favorable than Zentalis Pharmaceuticals.

Institutional & Insider Ownership

67.1% of Zentalis Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.9% of Mirati Therapeutics shares are owned by institutional investors. 4.1% of Mirati Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Mirati Therapeutics beats Zentalis Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Zentalis Pharmaceuticals vs. Ultragenyx Pharmaceutical Stock

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Valuation and Earnings

This table compares Zentalis Pharmaceuticals and Ultragenyx Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Ultragenyx Pharmaceutical	$103.71 million	70.18	$-402,730,000.00	($7.36)	-14.77

Zentalis Pharmaceuticals has higher earnings, but lower revenue than Ultragenyx Pharmaceutical.

Profitability

This table compares Zentalis Pharmaceuticals and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	N/A	N/A
Ultragenyx Pharmaceutical	-119.19%	-50.69%	-26.87%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Zentalis Pharmaceuticals and Ultragenyx Pharmaceutical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	0	0	7	0	3.00
Ultragenyx Pharmaceutical	0	6	8	0	2.57

Zentalis Pharmaceuticals currently has a consensus target price of $56.4286, indicating a potential upside of 14.93%. Ultragenyx Pharmaceutical has a consensus target price of $131.20, indicating a potential upside of 20.73%. Given Ultragenyx Pharmaceutical's higher possible upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Zentalis Pharmaceuticals.

Institutional & Insider Ownership

67.1% of Zentalis Pharmaceuticals shares are owned by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Zentalis Pharmaceuticals beats Ultragenyx Pharmaceutical on 5 of the 9 factors compared between the two stocks.

Zentalis Pharmaceuticals vs. Arrowhead Pharmaceuticals Stock

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Valuation and Earnings

This table compares Zentalis Pharmaceuticals and Arrowhead Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Arrowhead Pharmaceuticals	$87.99 million	79.80	$-84,550,000.00	($0.84)	-80.54

Zentalis Pharmaceuticals has higher earnings, but lower revenue than Arrowhead Pharmaceuticals.

Profitability

This table compares Zentalis Pharmaceuticals and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	N/A	N/A
Arrowhead Pharmaceuticals	-96.09%	-17.37%	-15.19%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Zentalis Pharmaceuticals and Arrowhead Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	0	0	7	0	3.00
Arrowhead Pharmaceuticals	0	2	10	0	2.83

Zentalis Pharmaceuticals currently has a consensus target price of $56.4286, indicating a potential upside of 14.93%. Arrowhead Pharmaceuticals has a consensus target price of $85.3077, indicating a potential upside of 26.27%. Given Arrowhead Pharmaceuticals' higher possible upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Zentalis Pharmaceuticals.

Institutional & Insider Ownership

67.1% of Zentalis Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Zentalis Pharmaceuticals beats Arrowhead Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Zentalis Pharmaceuticals vs. GW Pharmaceuticals Stock

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and GW Pharmaceuticals (NASDAQ:GWPH) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Valuation and Earnings

This table compares Zentalis Pharmaceuticals and GW Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GW Pharmaceuticals	$311.33 million	22.04	$-9,020,000.00	($0.24)	-912.08

Zentalis Pharmaceuticals has higher earnings, but lower revenue than GW Pharmaceuticals.

Profitability

This table compares Zentalis Pharmaceuticals and GW Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	N/A	N/A
GW Pharmaceuticals	-11.05%	-7.46%	-6.13%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Zentalis Pharmaceuticals and GW Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	0	0	7	0	3.00
GW Pharmaceuticals	0	10	4	0	2.29

Zentalis Pharmaceuticals currently has a consensus target price of $56.4286, indicating a potential upside of 14.93%. GW Pharmaceuticals has a consensus target price of $204.0909, indicating a potential downside of 6.69%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Zentalis Pharmaceuticals is more favorable than GW Pharmaceuticals.

Institutional & Insider Ownership

67.1% of Zentalis Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are owned by institutional investors. 3.1% of GW Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Zentalis Pharmaceuticals beats GW Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Zentalis Pharmaceuticals vs. Ascendis Pharma A/S Stock

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, institutional ownership, dividends, valuation and earnings.

Earnings & Valuation

This table compares Zentalis Pharmaceuticals and Ascendis Pharma A/S's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Ascendis Pharma A/S	$14.98 million	437.57	$-244,180,000.00	($5.25)	-23.23

Zentalis Pharmaceuticals has higher earnings, but lower revenue than Ascendis Pharma A/S.

Profitability

This table compares Zentalis Pharmaceuticals and Ascendis Pharma A/S's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	N/A	N/A
Ascendis Pharma A/S	-4,042.79%	-55.72%	-49.42%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Zentalis Pharmaceuticals and Ascendis Pharma A/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	0	0	7	0	3.00
Ascendis Pharma A/S	0	1	11	0	2.92

Zentalis Pharmaceuticals presently has a consensus price target of $56.4286, indicating a potential upside of 14.93%. Ascendis Pharma A/S has a consensus price target of $187.6667, indicating a potential upside of 52.69%. Given Ascendis Pharma A/S's higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Zentalis Pharmaceuticals.

Institutional and Insider Ownership

67.1% of Zentalis Pharmaceuticals shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Zentalis Pharmaceuticals beats Ascendis Pharma A/S on 5 of the 9 factors compared between the two stocks.